Evidence map›Paper›PMID 35774402›Full record

ReviewFrontiers in cellular and infection microbiology2022

Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2.

Jiajing Zheng, Jiameng Miao, Rui Guo, Jinhe Guo, Zheng Fan, Xianbin Kong, Rui Gao, Long Yang

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Mucosal implications of oral Jak3-targeted drugs in COVID patients.Molecular medicine (Cambridge, Mass.) · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jiajing ZhengCollege of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Jiameng MiaoCollege of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Rui GuoResearch Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Jinhe GuoCollege of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Zheng FanDepartment of Critical Medicine, The First Affiliated Hospital of Suzhou University, Suzhou, China.
Xianbin KongCollege of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Rui GaoInstitute of Clinical Pharmacology of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Long YangResearch Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Tianjin University of Traditional Chinese Medicine · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel coronavirus pneumonia (COVID-19) is spreading worldwide, causing great harm and stress to humans. Since patients with novel coronavirus (SARS-CoV-2) have a high probability of developing acute respiratory distress syndrome (ARDS) in severe cases, the pathways through which SARS-CoV-2 causes lung injury have become a major concern in the scientific field. In this paper, we investigate the relationship between SARS-CoV-2 and lung injury and explore the possible mechanisms of COVID-19 in ARDS from the perspectives of angiotensin-converting enzyme 2 protein, cytokine storm, activation of the immune response, triggering of Fas/FasL signaling pathway to promote apoptosis, JAK/STAT pathway, NF-κB pathway, type I interferon, vitamin D, and explore the possibility of prevention and treatment of COVID-19. To explore the possibility of SARS-CoV-2, and to provide new ideas to stop the development of ARDS in COVID-19 patients.

Indexed as

COVID-19Lung InjuryRespiratory Distress SyndromeHumansJanus KinasesSARS-CoV-2Signal TransductionSTAT Transcription FactorsJanus KinasesSTAT Transcription Factorsacute respiratory distress syndromeangiotensin-converting enzyme II proteincytokine stormimmune responseNF-κB pathwaynovel coronavirustype I interferon

Identifiers

PMID35774402
PMCPMC9237249
OpenAlexW4282828410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.